Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Lake Bioscience CoSHSE:600866 -2.80%66 EV-to-EBIT is 36.41 as of Sep. 15, 2026, which is 192% above its 10-year median of 12.45. GuruFocus rates SHSE:600866 with a GF Score™ of 66/100 and a GF Value™ of ¥5.90 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 369 Biotechnology companies, Star Lake Bioscience Co ranks worse than 76.69% on this metric.
Star Lake Bioscience Co (SHSE:600866) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Star Lake Bioscience Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥13,239 Mil.
Star Lake Bioscience Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥354 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Lake Bioscience Co EV-to-EBIT Related Terms
Star Lake Bioscience Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600866 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Star Lake Bioscience Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Lake Bioscience Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Star Lake Bioscience Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Star Lake Bioscience Co's EV-to-EBIT falls into.
Star Lake Bioscience Co's current Enterprise Value is ¥12,873 Mil.
Star Lake Bioscience Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥354 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Lake Bioscience Co (SHSE:600866) has a EV-to-EBIT of 36.41 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Star Lake Bioscience Co and its competitors. This is 192% above median its historical median of 12.45. According to the industry distribution chart, Star Lake Bioscience Co ranks #283 out of 369 companies in the Biotechnology industry, placing it in the top 76.7%.
Is Star Lake Bioscience Co's EV-to-EBIT too high?
Star Lake Bioscience Co's current EV-to-EBIT of 36.41 is 192% above median its 10-year median of 12.45. The Biotechnology industry median EV-to-EBIT is 14.64. Star Lake Bioscience Co's value of 36.41 is 148.7% above this industry median. Based on the distribution chart, Star Lake Bioscience Co ranks #283 out of 369 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Star Lake Bioscience Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Star Lake Bioscience Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Star Lake Bioscience Co ranks #283 out of 369 companies for EV-to-EBIT. This places Star Lake Bioscience Co in the lower half of its industry. The industry median EV-to-EBIT is 14.64. Star Lake Bioscience Co's value of 36.41 is 148.7% above this benchmark. While the company's 10-year median is 12.45 vs. the industry median of 14.64, Star Lake Bioscience Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.64, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Lake Bioscience Co's current EV-to-EBIT of 36.41 is 148.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Star Lake Bioscience Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Lake Bioscience Co's current EV-to-EBIT is 36.41, which is 192% above median its own 10-year median of 12.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Lake Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Star Lake Bioscience Co (SHSE:600866) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.90, compared to a current price of ¥4.17 — trading 29.3% below its estimated fair value. The current EV-to-EBIT is 36.41, which is 192% above median its 10-year median of 12.45 and 148.7% above the Biotechnology industry median of 14.64. Star Lake Bioscience Co's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Star Lake Bioscience Co (SHSE:600866), the current EV-to-EBIT is 36.41 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Lake Bioscience Co (SHSE:600866) Overvalued in 2026?
Based on GuruFocus' analysis, Star Lake Bioscience Co stock appears to be undervalued.
The current stock price of ¥4.17 is trading 29.3% below its estimated GF Value™ of ¥5.90.
GuruFocus considers Star Lake Bioscience Co to be Modestly Undervalued.
Key valuation signals for SHSE:600866:
EV-to-EBIT: 36.41 (192% above median its 10-year median of 12.45)
GF Value™: ¥5.90 vs. price of ¥4.17 (29.3% below fair value)
Industry Position: 148.7% above the Biotechnology median (#283 of 369)
No single metric tells the full story. See the SHSE:600866 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
66GF Score
Get the complete analysis for SHSE:600866
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600866 has been successfully added to your 
